Trial Profile
A Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Determine the Efficacy of Repeat Inhaled Doses of GW870086X on FEV1 in Mild to Moderate Asthmatics.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 870086 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 14 Apr 2012 New source identified and integrated (EudraCT2008-008254-23: European Clinical Trials Database).
- 12 Jan 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 12 Jan 2010 Actual patient number (37) added as reported by ClinicalTrials.gov.